

CSD/BSE&NSE/2022-2023  
November 4, 2022

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/ Madam,

**Sub: Clarification /Confirmation on news item appearing in “Media/Publication”**  
**Ref: Your email L/SURV/ONL/RV/SR/ (2022-2023)/26 dated November 04, 2022**  
**Ref: Your letter no. NSE/CM/Surveillance/12446 dated November 04, 2022**

We refer to your email/letter cited under reference on the subject received through email, asking us clarify on the news item that appeared today in the “Website-[www.moneycontrol.com](http://www.moneycontrol.com)” dated November 04, 2022 captioned “Blackstone, Advent International in talks to buy controlling stake in Suven Pharma: Report.”

- a) As a forward looking company, we keep exploring various strategic ideas that are in the interest of company and create value for all its stakeholders. However, we do not comment on media speculations.
- b) We follow the highest standards of corporate governance, and the Company is conscious of its disclosure obligations under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). Please be assured that the Company will always make a disclosure if and when the same is required under the Listing Regulations. We wanted to reiterate that as on date, there has been no development which requires a disclosure under the Listing Regulations.
- c) The material impact of this article on the Company. NIL

We request you to take the above on record.

Thanking you,  
Yours faithfully,  
**For Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

## **Suven Pharmaceuticals Limited**

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5  
Avenue 7 | Banjara Hills | Hyderabad - 500034 | Telangana | India | CIN: L24299TG2018PLC128171  
Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | [www.suvenpharm.com](http://www.suvenpharm.com)